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Purpose: To identify factors that influence postrelapse
survival (PRS) in patients with nonmetastatic osteosarcoma
of the extremity
Patients and Methods: One hundred sixty-two patients
with recurrent osteosarcoma of the extremity were retro-
spectively reviewed. The first-line treatment included sur-
gery of the primary lesion and chemotherapy with metho-
trexate, doxorubicin, cisplatin, and ifosfamide.
Results: The projected 5-year PRS rate was 28%. Patients
who had complete surgery of recurrence had a 5-year PRS
of 39%, whereas for those who did not have complete
surgery, PRS was 0% at 3 years (P < .0001). In the latter
group, PRS was not influenced by site of recurrence and
relapse-free interval (RFI), although it was influenced (P 
.006) by the use of second-line chemotherapy (PRS, 53% at
12 months for patients who received chemotherapy v 12%
for those who did not). In patients who had complete
surgery, PRS was influenced by site of relapse (5-year PRS,
lung 44%, other 19%; P < .06), RFI (5-year PRS at < 24
months, 20%; at > 24 months, 60%; P < .0001), and
number of lung metastases (5-year PRS, two or fewer
nodules, 59%; more than two nodules, 14%; P < .0001) but
not by the use of a second-line chemotherapy treatment.
Conclusion: RFI, site of metastases, and number of pul-
monary nodules are the main prognostic factors for PRS in
osteosarcoma. Complete surgery of recurrence is pivotal in
the strategy of treatment. Patients with unresectable recur-
rence benefit from second-line chemotherapy, whereas our
data do not support a generalized use of chemotherapy
after complete surgery of first recurrence.
J Clin Oncol 21:710-715. © 2003 by American
Society of Clinical Oncology.
HIGH-GRADE osteosarcoma is a malignant bony tumorwith a peak of incidence in the second decade of life.
When treated by surgery alone, usually amputation, the cure rate
was approximately 10%, but the use of chemotherapy has
significantly improved the clinical outcome.1
Recurrent disease still occurs in approximately 30% to 40% of
patients with nonmetastatic osteosarcoma of the extremity de-
spite a complete surgical removal of the tumor and intensive
chemotherapeutic treatment.2-6 The postrelapse survival (PRS)
in this subset of chemotherapy-resistant patients is usually low.
An aggressive and even repeated pulmonary metastasectomy is
at present an accepted strategy of treatment in patients with
metastases confined to the lung,7-16 whereas the value of second-
line chemotherapy treatment9,10,12-16 and the best strategy of
treatment for those patients with recurrence other than that of the
lung 11,14,15,17 are not well defined.
This study is a retrospective analysis of patients who relapsed
from high-grade osteosarcoma of the extremity. The aim of the
study was to identify factors influencing the PRS.
PATIENTS AND METHODS
Patients
Patients with a diagnosis of nonmetastatic osteosarcoma of the extrem-
ity who entered four sequential studies carried out at our institute between
October 1986 and June 1995 were identified using the database of the
tumor center and chemotherapy department of the authors’ institutions.
Between October 1986 and June 1995, four protocols for the treatment of
nonmetastatic osteosarcoma of the extremity were sequentially activated at
the Rizzoli Institute: IOR/OS-2, IOR/OS-3, IOR/OS-3bis, and IOR/OS-4.
Characteristics and results have been previously reported in detail.3,18-20
The criteria of eligibility for IOR/OS-2, IOR/OS-3, IOR/OS-3bis, and
IOR/OS-4 were the following: biopsy-proven, classic, high-grade osteosar-
coma of the extremity; age younger than 40 years; absence of metastases
confirmed by bone scintigraphy and by computed tomography of the lungs;
an interval of less than 1 month between biopsy and start of chemotherapy;
normal renal and hepatic function; and no prior chemotherapy or surgical
treatment for the bone lesion.
The strategy of treatment was based on primary chemotherapy treatment,
resection of the primary tumor, and postoperative chemotherapy treatment
(neoadjuvant treatment). In the first three protocols (IOR/OS-2, IOR/OS-3,
and IOR/OS-3bis), patients received primary chemotherapy with high-dose
methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM). Postopera-
tively, patients with a good histologic response received the same drugs
preoperatively used, whereas in those with a poor histologic response,
ifosfamide (IFO) was added to the three drugs preoperatively used. In the
fourth protocol, all the patients received IFO from the preoperative phase
added to MTX, CDP, and ADM.
After chemotherapy, patients were checked by radiographs of the chest
and the treated limb and observed in the outpatient clinic every 2 months for
2 years, every 3 months in the third year, and then every 6 months thereafter.
In the last protocol (IOR/OS-4), most of the patients were checked with
computed tomography scans of the lung performed every 3 months in the
first 3 years, every 4 months in the fourth and fifth years, and then every 6
months thereafter.
Because the pattern of relapse of osteosarcoma is heterogeneous, the
strategy of treatment of first relapse was individualized. Nevertheless, the
cornerstone of treatment was the surgical removal of the metastases
whenever possible. A second round of chemotherapy treatment was usually
suggested only when it was not possible to achieve complete surgical
remission or when the metastatic pattern suggested a particularly aggressive
behavior (multiple metastases or short disease-free interval). Since 1991,
patients have been receiving four cycles of high-dose IFO (15 g/m2 over 5
days continuous infusion). In previous years, patients usually received
different treatments based on drug combinations not used in first-line
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chemotherapy, such as bleomycin, 15 mg/m2/d for 2 days, cyclophospha-
mide, 600 mg/m2/d for 2 days, and dactinomycin, 600 g/m2/d for 2 days;
CDP, 120 mg/m2, 72 hours continuous infusion, and etoposide, 120 mg/m2/d for
3 days; cyclophosphamide, 300 mg/m2 every 12 hours for six doses, and
etoposide, 200 mg/m2/d for 3 days; or standard-dose IFO, 2 g/m2/d for 5 days.
Four hundred thirty-five patients entered the IOR/OS-2, IOR/OS-3,
IOR/OS-3bis, and IOR/OS-4 protocols. With a follow-up ranging between 6
and 12 years (median, 8.5 years), the 10-year disease-free survival was 57%
(95% confidence interval [CI], 52% to 62%). One hundred seventy-five
patients (40%) had recurrence.
Statistical Methods
The aim of this study was to identify factors that influence the PRS in
patients with initial diagnosis of nonmetastatic classic high-grade osteosar-
coma of the extremity. For this analysis, patients were eligible when it was
possible to collect information on date and type of first relapse (local
recurrence and/or distant metastases), treatment after relapse, and date and
cause of death. Information was collected from database files, pathology and
radiology reports, and general medical records. Complete surgical remission
was defined as removal of all evident metastatic disease, with no tumor tissue
at the resection margins on histologic examination.
PRS was calculated from the date of recurrence until death or last
follow-up. The following parameters were investigated: relapse-free interval
(RFI; time between surgical resection of the primary tumor and date of onset
of relapse), pattern of first relapse (lung metastases, bone metastases, local
recurrence, and other sites of metastases), site (monolateral or bilateral) of
lung metastases, number of resected pulmonary nodules, surgical complete
remission, and second-line chemotherapy treatment.
The Statview 4.5 statistical package (Abacus Concepts, Berkeley, CA)
was used for the statistical analysis. Differences between the groups were
compared by means of the 2 test and t test. Survival curves were calculated
according to the Kaplan-Meier method and compared by means of the
log-rank test.
RESULTS
Of the 175 patients who had recurrence, 59 (34%) were treated
according to IOR/OS-2 protocol, 45 (26%) were in IOR/OS-3,
24 (14%) were in IOR/OS-3 bis, and 47 (27%) were in
IOR/OS-4 protocols. One hundred sixty-two patients (92.5%)
were eligible for the analysis; 13 (six in IOR/OS-2, three in
IOR/OS-3, one in IOR/OS-3bis, and three in IOR/OS-4) were
excluded because after relapse they preferred to move to other
centers, and no information about treatment received was avail-
able. Patient characteristics and pattern of first relapse are
reported in Table 1. There was a prevalence of lung location;
overall, 136 patients (84%) had pulmonary metastases, confined
only to the lung in 125 patients. Regarding relapse-free interval,
85 patients (52.5%) relapsed in the first 2 years of follow-up (20
in the first year), 42 (26%) relapsed in the third year, 19 (12%)
relapsed in the fourth year, and seven relapsed in the fifth year.
Afterwards, recurrence was recorded only in nine patients
(5.5%); the latest recurrence occurred after 11 years and 5
months of follow-up.
Surgery of metastatic lesions was performed in 125 patients
(77%). In 11 of them, the surgical procedure was oncologically
inadequate, with residual of the metastases. Overall, 114 patients
(70%) achieved complete surgical remission. Of the 125 patients
with metastases confined to the lung, 93 (74.5%) were free of
disease after complete surgical treatment, as opposed to 21
(57%) of the 37 patients with other than lung metastases (P 
.04). Among the 93 patients in complete surgical remission, the
RFI was  24 months in 44 patients (47%) and longer than 24
months in 49 patients (53%); 64 patients (69%) had one to two
pulmonary nodules, and 29 (31%) had three or more nodules.
None of the patients with bone and lung metastases achieved a
disease-free status, whereas a complete surgery was performed
in 17 of the patients (74%) with bone metastases or local
recurrence, in two of the three patients with local recurrence and
lung metastases, and in two patients with lymph node metasta-
ses. Patients who had complete surgical remission had a longer
RFI (mean  SD, 28  18 months) than those who did not
(mean  SD, 23  13.5 months), but the difference was not
statistically significant (P  .85).
In the 93 patients with lung metastases only and who received
oncologically adequate surgical treatment, the surgical proce-
dures were monolateral wedge resection in 54 patients (58%),
bilateral wedge resection in 22 patients (24%), lobectomy with
or without wedge resection in 15 patients (16%), and pneumo-
nectomy in two patients. The mean number of resected meta-
static nodules was 2.7 (range, one to 12 nodules). Of the 23
patients with bone metastases and or local recurrence, 17 (74%)
had complete surgery after amputation (10 patients) or resection
with prosthetic reconstruction (seven patients), whereas six
patients could not achieve a complete surgical remission. Con-
temporary resection of local recurrence and lung metastases
(monolateral wedge resection) was performed in two patients.
Two patients with lymph node metastases underwent resection.
Second-line chemotherapy treatment was given in 56 of the
patients (35%), high-dose IFO was given to 31 patients (55%),
and other treatments were given to 25 patients (45%). In 36
patients, chemotherapy followed surgical complete remission,
and in six patients, it preceded surgical complete remission; in 14
patients, a surgical treatment was not feasible despite the
chemotherapy treatment. In patients who achieved surgical
complete remission, second-line chemotherapy was given when
the pattern of recurrence suggested a more aggressive behavior
of the tumor, such as in patients with other than lung locations
and, in case of lung location of metastases, in patents with three
or more nodules or a short RFI (Table 2). In patients in surgical
complete remission and with lung metastases, two patients with
lung metastases and local recurrence received chemotherapy,
whereas among patients with only lung metastases, 29 patients
Table 1. Patient Characteristics and Pattern of First Relapse
Characteristic
No. of
Patients %
Age at first relapse, years
Median 17.5
Range 5 to 47
Relapse-free interval, months
Median 23
Range 2 to 137
Site
Lung only 125 77
Monolateral 80 64
Bilateral 45 36
Other site  lung 37 23
Bone  local recurrence 23 62
Bone and lung 8 22
Local recurrence and lung 3 8
Lymph nodes 2 5
Heart 1 3
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(31%) received chemotherapy and 64 (69%) did not. All 48
patients (30%) who did not have complete surgical remission
died of disease, with a median PRS ranging between 1 and 26
months (median, 6 months).
Of the 114 patients surgically free of disease, 25 (22%) were
continuously free of disease, with a median PRS of 60 months
(range, 20 to 112 months). Eighty-nine patients (78%) relapsed
with a median second RFI of 8 months (range, 1 to 54 months).
Of those patients, 20 (22.5%) were alive after repeated surgical
procedures for the metastatic disease, with a median time after
the last metastatic event ranging from 2 to 106 months (median,
45 months). Overall, with a median first PRS time of 65 months
(range, 12 to 131 months), 45 of the patients (39.5%) in complete
surgical remission after first recurrence were alive, 40 were alive
without evidence of disease, and five were alive with disease.
The actuarial probability of PRS on the whole population was
33% (95% CI, 25% to 40%) at 3 years and 28% (95% CI, 21%
to 35%) at 5 years. Those patients who had complete surgical
remission had a probability of PRS at 5 years of 39% (95% CI,
30% to 49%); whereas those who did not had a 2% (95% CI, 0%
to 7%) 2-year probability of PRS and a 0% probability at 3 years
(P .001). According to the site of first recurrence, patients who
had recurrence confined to the lung had a 5-year PRS of 33%
(95% CI, 24% to 42%), and those with a recurrence location
other than the lung had a PRS of 11% (95% CI, 1% to 21%) at
5 years (P  .013). According to the RFI, the 5-year PRS
probability was 5% (95% CI, 0% to 14%) for patients having a
first RFI ranging between 1 and 12 months, 15% (95% CI, 7% to
24%) when the RFI was between 13 and 24 months, 38% (95%
CI, 23% to 53%) when it was between 25 and 36 months, and
59% (95% CI, 41% to 77%) for patients having a longer RFI
(P  .001).
In patients who failed to achieve complete surgical remission,
the PRS probability was not different according to the site of first
recurrence and the length of the RFI, whereas it was influenced
by the use of chemotherapy (53% PRS [95% CI, 28% to 78%] at
12 months for patients who received chemotherapy v 12% PRS
[95% CI, 1% to 23%] for patients who did not; P  .006). At 2
years, the PRS probability was 0 in the two groups.
In patients who reached complete surgical remission, the
postrelapse 5-year probability of event-free survival (EFS) was
16% (95% CI, 8% to 23%). In patients with only lung recur-
rence, the 5-year EFS was 18% (95% CI, 9% to 27%), and it was
6% (95% CI, 0% to 18%) for other locations of recurrence (P 
.5). Patients with an RFI longer than 24 months had a 24% (95%
CI, 12% to 36%) 5-year EFS, which was significantly better
(P  .0001) than that of those with a shorter RFI (9% EFS; 95%
CI, 1% to 17%). When metastases were localized to the lung, a
significantly better 5-year EFS (P  .008) was found in patients
with only one to two pulmonary nodules (24%; 95% CI, 12% to
36%) compared with that of patients with a higher number of
lung metastases (3% EFS; 95% CI, 0% to 10%). Patients with
monolateral lung metastases had a better 5-year EFS (20%; 95%
CI, 9% to 31%) than those with bilateral metastases (8% EFS;
95% CI, 0% to 19%). A 5-year EFS of 10% (95% CI, 0% to
20%) was found in patients who received a second-line chemo-
therapy treatment, whereas it was 19% (95% CI, 8% to 29%)
when chemotherapy was not administered (P  .1)
In patients who reached complete surgical remission, a differ-
ent probability of PRS was documented according to several
variables (Table 3). Patients with metastases confined to the lung
had a better prognosis than patients with metastases in other
locations. According to the RFI, the 5-year PRS probability was
8% (95% CI, 0% to 24%) for patients having a first RFI ranging
between 1 and 12 months, 23% (95% CI, 10% to 35%) when the
RFI was between 13 and 24 months, 50% (95% CI, 32% to 68%)
when it was between 25 and 36 months, and 74% (95% CI, 55%
to 92%) for patients with a longer RFI (P  .0001). Of the
patients with metastases confined to the lung, those with mono-
lateral lung metastases had a slightly better, but not statistically
significant, probability of PRS than patients with bilateral lung
metastases. A different probability of PRS was observed with
regard to the number of resected metastatic nodules: Patients
with one to two metastatic nodules had a significantly higher
probability of PRS than patients with three or more pulmonary
nodules (Table 3).
In the whole group of patients who had complete surgical
remission, the use of a second-line chemotherapy treatment did
Table 2. Pattern of Relapse and Use of Second-Line Chemotherapy Treatment
in 114 Patients in Surgical Complete Remission
Variable
Surgery  Chemotherapy
(n  42)
Surgery
(n  72)
PNo. of Patients % No. of Patients %
Site .01
Lung only 29 31 64 69
Other sites  lung 13 62 8 38
Relapse-free interval .7
 24 months 22 39 34 61
 24 months 20 34 38 66
Laterality* .3
Monolateral 21 29 51 71
Bilateral 10 43 13 57
Lung metastases*  .0001
 2 nodules 14 21 52 79
 2 nodules 17 59 12 41
*Of 95 patients, 93 had only lung metastases, and two had monolateral lung metastases and local recurrence.
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not influence the PRS. A subgroup analysis of PRS according to
pattern of recurrence and use of second-line chemotherapy was
performed. In the 93 patients with lung metastases only (Table
4), a better PRS for those receiving chemotherapy was observed
only in the subgroup of patients with more than two pulmonary
nodules; three (17.5%) of the 17 patients who received chemo-
therapy were alive compared with none of the 12 who did not
receive chemotherapy (5-year PRS, 18% and 7%, respectively;
P  .9). Of the 21 patients with a location of recurrence other
than the lung, eight did not have chemotherapy after their
relapse, and none survived after 5 years from recurrence. Five of
the 13 patients treated with chemotherapy were alive, with a
5-year PRS of 33%.
Multivariate analysis, restricted to patients with lung metas-
tases who had complete surgical remission, was carried out to
investigate the prognostic significance of the following vari-
ables: RFI ( 24 months v  24 months), number of resected
pulmonary nodules (one or two v three or more), and site of
pulmonary nodules (monolateral v bilateral). Predictive factors
of PRS were the RFI ( 24 months; relative risk, 2.61 [95% CI,
1.4 to 4.7]; P .002) and the number of pulmonary nodules (one
to two nodules; relative risk, 0.3 [95% CI, 0.2 to 0.5]; P 
.0001), whereas no statistical significance was reported for the
site of pulmonary nodules.
On the basis of these results, we calculated the probability of
survival in the population of patients who had lung metastases
only and who were in complete surgical remission by combining
the risk factors, RFI, and number of lung nodules (Fig 1).
Patients with an RFI longer than 24 months and only one to two
nodules had a good PRS (5-year PRS, 72% [95% CI, 58% to
86%]). Patients with short RFI ( 24 months) and three or more
lung nodules had a poor PRS (5-year PRS, 5% [95% CI, 0% to
15%]). An intermediate probability of survival was seen for
patients with one to two nodules and a short RFI (5-year PRS,
41% [95% CI, 20% to 61%]) and for those with a long relapse
Table 3. Probability of Postrelapse Survival and 95% Confidence Intervals
in 114 Patients With Complete Surgical Remission
Variable
No. of
Patients % of Survival
5-Year PRS
P% 95% CI
Site .06
Lung only 93 44 44 33 to 54
Other site  lung 21 19 19 1 to 37
Relapse-free interval  .0001
 24 months 56 18 20 9 to 30
 24 months 58 60 60 46 to 74
Laterality* .2
Monolateral 72 46 45 33 to 57
Bilateral 23 35 37 18 to 57
Lung metastases*  .0001
 2 nodules 66 58 59 46 to 72
 2 nodules 29 10 14 1 to 26
Abbreviation: PRS, postrelapse survival.
*Of 95 patients, 93 had only lung metastases, and two had monolateral lung metastases and local recurrence.
Table 4. Postrelapse Survival and Use of Second-Line Chemotherapy According
to Pattern of Relapse in 93 Patients With Only Lung Metastases Who Reached
Surgical Complete Remission
Variable/Yes-No
Chemotherapy
No. of
Patients
5-Year PRS
P% 95% CI
Monolateral
Yes 19 34 7 to 61 .2
No 51 48 34 to 62
Bilateral
Yes 10 30 0 to 45 .3
No 13 42 24 to 76
 2 nodules
Yes 12 30 0 to 61 .02
No 52 65 51 to 78
2 nodules
Yes 17 18 0 to 36 .9
No 12 7 0 to 21
RFI  24 months
Yes 16 6 0 to 18 .001
No 28 30 13 to 48
RFI  24 months
Yes 13 49 19 to 78 .2
No 36 67 51 to 83
Abbreviations: PRS, postrelapse survival; RFI, relapse-free interval.
Fig 1. Postrelapse survival by relapse-free interval (RFI) and number of
pulmonary metastases (PM) in patients with complete surgery; A 42 patients, RFI
more than 24 months, 1 to 2 PM; B  22 patients, RFI less than 24 months; 1 to
2 PM; C  9 patients, RFI more than 24 months; > 3 PM; and D  20 patients, RFI
less than 24 months; > 3 PM.
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RFI but three or more nodules (5-year PRS, 33% [95% CI, 2%
to 64%]).
DISCUSSION
This study is a retrospective analysis performed on the largest
series reported in the literature of patients with extremity
osteosarcoma relapsing after complete surgery and neoadjuvant
chemotherapy based on the most active drugs against osteosar-
coma—high-dose MTX, ADM, CDP, and IFO.
The pattern of recurrence observed in our study was similar to
that reported in previous studies11,14,15,17 and confirmed that the
lungs are the main target of metastases from osteosarcoma. A
close relation among pattern of recurrence, surgical resectability
of the recurrence, and PRS was observed. In total, 125 patients
(77%) underwent surgery, which resulted in complete resection
of the metastatic lesions in 114 of the patients. Therefore, 70%
of the patients had complete surgical remission. The percentage
of patients who could be made surgically disease-free was 74.5%
when metastases were confined to the lung compared with 57%
in patients with metastases that were in other locations (P 
.044). All 48 patients who did not have complete surgical
remission died of disease, whereas those who could be made
surgically disease free had a 39% 5-year probability of survival.
In a large series reported by Huth and Eilber,11 complete surgery
was achieved in 60% of the patients with metastases confined to
the lung and in 31% of those with metastases in locations other
than the lung. The 3-year survival in patients who had complete
surgery for lung metastases was 36%, and it was 0% for those
who did not. In the Scandinavian Sarcoma Group experience,15
28 (47%) of 60 metastatic patients underwent complete surgery:
27 (51%) of the 53 patients with lung metastases and one (14%)
of seven patients with recurrence in another site. The 5-year
survival for patients who were treated with or without complete
surgery was 50% and 0%, respectively.
The analysis of survival restricted to the patients who
achieved a complete surgical remission reinforces the prognostic
significance of the pattern of recurrence; the 5-year survival
probability was 44% in case of lung metastases alone and 19%
when recurrence involved other sites. The different pattern of
relapse could be the expression of a different biologic behavior
of the tumor, indicating that the tumor is more aggressive in
patients with tumor recurrence in sites other than the lung, as
already reported in the case of local recurrence.21,22
Another factor that influenced survival was the RFI. The
median RFI observed in our series was 23.5 months, with 5% of
the patients having an RFI longer than 60 months; the latest
recurrence occurred after 11 years and 5 months of follow-up.
These data show the need for prolonged follow-up in patients
with nonmetastatic osteosarcoma. A close relation was found in
our series between duration of RFI and PRS; the 5-year PRS was
only 8% in patients with an RFI of 1 year or shorter, and it
increased to 23%, 50%, and 74% with a 2-year RFI, a 3-year
RFI, or a longer RFI, respectively. Contrasting data are reported
with regard to this issue. In the analysis by Saeter et al,15 the RFI,
with a cutoff set at 21 months, lost significance after multivariate
analysis. Other articles have reported a possible influence of the
length of RFI on survival, but only when the cutoff was set at 8
months,14 whereas in the analysis of Skinner et al,13 the RFI did
not correlate with PRS. In a large analysis on long-term results
after resection of lung metastases from different types of
malignancies, the RFI significantly influenced the survival, with
a cutoff set at 36 months.23
The lung was the most common site of osteosarcoma metas-
tases, and in our series, 93 patients with lung metastases
underwent complete surgery, which gave them a probability of a
3- and 5-year survival of 52% and 44%, respectively. In a similar
population, Huth and Eilber11 reported a 3-year PRS of 36%,
Beron et al9 reported a 3-year PRS of 30%, Skinner et al13 and
Belli et al12 reported a 5-year PRS of 37%, and Ward et al14
reported a 5-year PRS of 23%. A higher percentage of PRS
(5-year PRS, 50%) was reported by Saeter et al.15 However, we
must remember that in the Scandinavian Sarcoma Group (SSG)
report, only 51% of the patients with lung metastases underwent
complete resection, and a possible selection of patients with a
better prognosis might be supposed in the Saeter et al analysis of
this subset of patients. In a more recent article,16 a 3-year PRS of
61% was reported.
The number of resected pulmonary nodules was a prognostic
factor of PRS, with a significantly better prognosis for patients
with one or two lung metastases. Similar results were reported by
Saeter et al,15 Ward et al,14 and Skinner et al,13 whereas in the
report by Goorin et al,17 the number of lung metastases did not
influence the PRS.
Subgroups with significantly different prognoses were identi-
fied by combining the number of lung metastases resected and
the length of RFI. A very good prognosis (5-year PRS, 72%) was
found in patients with RFI longer than 24 months and one or two
pulmonary nodules, whereas a very poor prognosis (5-year PRS,
5%) was observed in patients with a shorter RFI and three or
more metastatic nodules. Patients with one to two pulmonary
nodules and short RFI and those with a long RFI but three or
more nodules had an intermediate probability of PRS (5-year
PRS, 41% and 33%, respectively). What we observed in patients
with a long RFI and one to two pulmonary nodules confirms
what was recently reported by Daw et al.24
Nowadays, despite the fact that it is quite common to give
second-line chemotherapy treatment, the role of this treatment in
the management of relapsing osteosarcoma patients is not
defined at all, and no controlled studies are available on this
topic. However, the rarity of the tumor and the heterogeneous
pattern of relapse make it almost impossible to carry out
randomized studies. Saeter et al15 reported that adequate chemo-
therapy (based on drugs not used in first-line therapy) signifi-
cantly influenced the PRS, whereas Belli et al12 failed to find any
advantage for patients who received chemotherapy. The results
reported in selected patients who underwent complete metasta-
sectomy and received second-line chemotherapy treatment10,14
were quite similar to those reported in comparable patients who
did not receive chemotherapy.13
Some indications of the role of chemotherapy in relapsing
osteosarcoma come from our study. It is interesting to notice that
unresectable patients who were treated with chemotherapy had a
PRS time significantly longer than that observed in patients who
refused chemotherapy; however, this was the only subgroup in
which second-line chemotherapy gave a significant advantage. In
patients who were made surgically disease-free, the addition of
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second-line chemotherapy did not offer any statistically signifi-
cant advantage in terms of PRS. A possible positive role of
chemotherapy could be supposed only for the group of patients
with three or more pulmonary nodules (three of 17 patients who
received chemotherapy were alive compared with zero of 12
who did not receive chemotherapy). These data are quite
disappointing if we consider that more than 50% of patients
received aggressive chemotherapy treatment based on high-dose
IFO, the activity of which, at least in terms of response, has been
well documented in relapsing sarcoma patients,25 and the re-
maining patients received drugs different from those used in
first-line treatment. However, these data come from a retrospec-
tive analysis, and the fact that the strategy of treatment was
individualized resulted in a selection bias among those who
received chemotherapy after tumor resection. Chemotherapy
was, in fact, more frequently used in patients whose relapse
pattern indicated an aggressive behavior of the tumor.
This retrospective analysis showed that RFI, site of metasta-
ses, and number of pulmonary nodules are the main prognostic
factors for PRS in osteosarcoma. Complete surgery of recurrence
is pivotal in the strategy of treatment. Our data do not support a
generalized use of second-line chemotherapy in relapsing osteo-
sarcoma but do support a generalized use only in selected
subgroups, such as unresectable patients, and, possibly, those
with three or more pulmonary nodules. It is important to
stimulate multicenter studies to determine the role of chemother-
apy, and at the same time, it is important to develop the research
of new drugs that are active against osteosarcoma.
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